Preclinical evaluation of VB6-845: An anti-EpCAM immunotoxin with reduced immunogenic potential

Cancer Biotherapy and Radiopharmaceuticals

Volumn 27, Issue 9, 2012, Pages 582-592

  Entwistle, Joycelyn ^a   Brown, Jennifer G ^a   Chooniedass, Shilpa ^a   Cizeau, Jeannick ^a   MacDonald, Glen C ^a  

^a Viventia Biotech Inc   (Canada)

Author keywords

De immunized Bouganin toxin; EpCAM; Immunotherapy; Immunotoxin; Targeted therapy

Indexed keywords

CITATUZUMAB BOGATOX; EPITHELIAL CELL ADHESION MOLECULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXPERIMENTAL MONKEY; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; MACACA FASCICULARIS; MALE; MICE; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868270670     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1200.271     Document Type: Article

References (64)

1. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv Cancer Res 2001;81:93.
2. Stirpe F, Battelli MG. Ribosome-inactivating proteins: Progress and problems. Cell Mol Life Sci 2006;63:1850.
3. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin treatment of cancer. Annu Rev Med 2007;58:221.
4. Fabbri A, Travaglione S, Falzano L, et al. Bacterial protein toxins: Current and potential clinical use. Curr Med Chem 2008;15:1116.
5. Pennell CA, Erickson HA. Designing immunotoxins for cancer therapy. Immunol Res 2002;25:177.
6. Fracasso G, Bellisola G, Castelletti D, et al. Immunotoxins and other conjugates: Preparation and general characteristics. Mini Rev Med Chem 2004;4:545.
7. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154.
8. Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: Preclinical studies and Phase I clinical trial. Clin Cancer Res 2010;16:1894.
9. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006;8:E532.
10. Pastan I, Hassan R, FitzGerald DJ, et al. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559.
11. Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009;9:982.
12. Momburg F, Moldenhauer G, Hämmerling GJ, et al. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res 1987;47:2883.
13. Ogura E, Senzaki H, Yoshizawa K, et al. Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res 1998;18:3669.
14. Xie X, Wang CY, Cao YX, et al. Expression pattern of epithelial cell adhesion molecule on normal and malignant colon tissues. World J Gastroenterol 2005;11:344.
15. Brown J, Rasamoelisolo M, Spearman M, et al. Preclinical assessment of an anti-EpCAM immunotoxin: Locoregional delivery provides a safer alternative to systemic administration. Cancer Biother Radiopharm 2009;24:477.
16. de Bono JS, Tolcher AW, Forero A, et al. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advance adenocarcinomas. Clin Cancer Res 2004;10:7555.
17. Ruf P, Gires O, Jäger M, et al. Characterisation of the new EpCAM-specific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007;97:315.
18. Brischwein K, Schlereth B, Guller B, et al. MT110: A novel bispecific single-chain antibody construct with thigh efficacy in eradicating established tumors. Mol Immunol 2006; 43:1129.
19. Kirman I, Whelan RL. Drug evaluation: Adecatumumab, an engineered human anti-EpCAM antibody. Curr Opin Mol Ther 2007;9:190.
20. Goel S, Bauer RJ, Desai K, et al. Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineered- monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. Ann Oncol 2007;18:1704.
21. Frankel AE. Reducing the immune response to immuntotoxin. Commentary re R. Hassan et al., Pretreatment with Rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 2004;10:13.
22. Bolognesi A, Polito L. Immunotoxins and other conjugates: Pre-clinical studies. Mini-Rev Med Chem 2004;4:563.
23. MacDonald GC, Glover N. Effective tumor targeting: Strategies for the delivery of armed antibodies. Curr Opin Drug Discov Devel 2005;8:177.
24. Li Z, Yu T, Zhao P, et al. Immunotoxins and cancer therapy. Cell Mol Immunol 2005;2:106.
25. Gould BJ, Borowitz MJ, Groves ES, et al. Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies. J Natl Cancer Inst 1989;81:775.
26. Brinkmann U, Keppler-Hafkemeyer A, Hafkemeyer P. Recombinant immunotoxins for cancer therapy. Expert Opin Biol Ther 2001;1:693.
27. Smallshaw JE, Ghetie V, Rizo J, et al. Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat Biotechnol 2003;21:387.
28. MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Dev Ther 2008;2:105.
29. MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck. Med Oncol 2009;26:257.
30. Kowalski M, Entwistle J, Cizeau J, et al. A phase I study of an intravesically administered immunotoxin targeting Ep-CAM for the treatment of non muscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des Devel Ther 2010;4:313.
31. Cizeau J, Grenkow DM, Brown JG, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of hte plant toxin bouganin. J Immunother 2009;32:574.
32. Bolognesi A, Polito L, Olivieri F, et al. New ribosomeinactivating proteins with polynucleotide:adenosine glycosidase and antiviral activities from Basella rubra L. and Bougainvillea spectabilis Willd. Planta 1997;203:422.
33. den Hartog MT, Lubelli C, Boon L et al. Cloning and expression of cDNA coding for bouganin. Eur J Biochem 2002;269:1772.
34. Bolognesi A, Polito L, Tazzari PL, et al. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type I ribosome-inactivating proteins. Br J Haematol 2000;110:351.
35. Food and Drug Administration (FDA). Guidance for Submission of Immunohistochemistry Applications to the FDA; Final Guidance for Industry. 1998. Available from: www. fda.gov/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm094002.htm. Accessed on December 7, 2011.
36. Balzar M, Winter MJ, de Boer CJ, et al. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 1999;77:699.
37. Winter MJ, Nagtegaal ID, Han J, et al. The Epithelial Cell Adhesion Molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol 2003; 163:2139.
38. Went PT, Lugli A, Meier S, et al. Frequent EpCAM protein expression in human carcinomas. Hum Pathol 2004;35:122.
39. Went P, Dirnhofer S, Schö pf D, et al. Expression and prognostic significance of EpCAM. J Cancer Mol 2008;3:169.
40. Levine S, Saltzman A. Distribution of small intestinal lesions in anaphylaxis of rats. Int. Arch Allergy Immunol 1998; 115:312.
41. Haggerty HG, Warner WA. BR96 sFv-PE40 Immunotoxin: Nonclinical safety assessment. Toxicol Pathol 1999;27:87.
42. Frankel AE, Kreitman RJ, Sausville EA. Targeted toxins. Clin Cancer Res 2000;6:326.
43. Vitetta ES. Immunotoxins and vascular leak syndrome. Cancer J 2000;6:S218.
44. Tsutsumi Y, Onda M, Nagata S, et al. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc Natl Acad Sci U S A 2000;97:8548.
45. Filpula D, Yang K, Basu A, et al. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem 2007;18:773.
46. Selvaggi K, Saria EA, Schwartz R, et al. Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYMEMel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol 1993;13:201.
47. Onda M, Nagata S, FitzGerald DJ, et al. Characterization of the B cell epitopes associated with a truncated from of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 2006;177:8822.
48. Onda M. Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 2009;10:131.
49. Mathew M, Verma RS. Humanized immunotoxins: A new generation of immunotoxins for targeted cancer therapy. Cancer Sci 2009;100:1359.
50. Litvinov SV, van Driel W, van Rhijn CM, et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 1996;148:865.
51. Ralhan R, Cao J, Lim T, et al. EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 2010;10:331.
52. ICH S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Available at http://www.fda .gov/cder/guidance/index.htm. Accessed on January 5, 2010.
53. Siegall CB, Liggett D, Chace D, et al. Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxin and its potential inhibition with nonsteroidal anti-inflammatory drugs. Clin Cancer Res 1997;3:339.
54. Barbieri L, Battelli MG, Stirpe F. Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1993;1154:237.
55. Withers GD, Kubes P, Ibbotson G, et al. Anaphylaxisinduced mesenteric vascular permeability, granulocyte adhesion, and platelet aggregates in rat. Am J Physiol Heart Circ Physiol 1998;275:H274.
56. Feitosa RFG, Melciades GB, Assreuy AMS, et al. The pharmacological profile of ovalbumin-induced paw oedema in rats. Mediators Inflamm 2002;11:155.
57. BattelliMG, Buonamici L, Polito L, et al.Hepatotoxicity of ricin, saporin or a saporin immunotoxin:Xanthine oxidase activity in rat liver and blood serum. Virchows Arch 1996;427:529.
58. Siegall CB, Liggitt D, Chace D, et al. Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci U S A 1994;91:9514.
59. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126.
60. Reimann KA, Turner S, Lambert JM, et al. In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Transplantation 1989;48:906.
61. Food and Drug Administration (FDA). Estimating the safe starting dose in clinical trial for therapeutics in adult healthy volunteers, 2005;5-7. CDER (Rockville, MD)
62. Food and Drug Administration (FDA). General guide for starting dose selection for a cytotoxic agent in cancer patients. 2006. Available from: www.fda.gov/cder/cancer/ docs/doseflow.pdf. Accessed on December 7, 2011.
63. Charles River. Baseline Haematology and Clinical Chemistry Values for Charles River CD-[Crl:CD-(SD)BR] Rats as a Function of Sex andAge.CharlesRiver TechnicalBulletin, 1984.
64. Lillie LE, Temple NJ, Florence LZ. Reference values for young normal Sprague-Dawley rats: Weight gain, hematology and clinical chemistry. Hum Exp Toxicol 1996;15:612.